美国食品药品监督管理局（FDA）已正式批准赛诺菲与再生元制药公司联合开发的Dupixent（度普利尤单抗）用于治疗过敏性真菌性鼻窦炎。该药物由此成为美国境内首个且唯一获批针对此适应症的疗法。
此次批准为受该慢性疾病困扰的患者提供了新的治疗选择。临床数据显示，Dupixent能显著改善患者症状，凸显其在鼻窦炎治疗领域的突破性意义。
美国食品药品监督管理局（FDA）已正式批准赛诺菲与再生元制药公司联合开发的Dupixent（度普利尤单抗）用于治疗过敏性真菌性鼻窦炎。该药物由此成为美国境内首个且唯一获批针对此适应症的疗法。
此次批准为受该慢性疾病困扰的患者提供了新的治疗选择。临床数据显示，Dupixent能显著改善患者症状，凸显其在鼻窦炎治疗领域的突破性意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.